Chemical Component Summary

FormulaC41 H64 O14
Molecular Weight780.938
Isomeric SMILESC[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O

Chemical Details

Formal Charge0
Atom Count119
Chiral Atom Count21
Bond Count126
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB00390 
Groups approved
DescriptionDigoxin is one of the oldest cardiovascular medications used today.[A178225] It is a common agent used to manage atrial fibrillation and the symptoms of heart failure.[A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.[L9143] This drug originates from the foxglove plant, also known as the _Digitalis_ plant[T610], studied by William Withering, an English physician and botanist in the 1780s.[A178237,A178240] Prior to this, a Welsh family, historically referred to as the _Physicians of Myddvai_, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.[A178240]
  • Digoxin
  • Digoxine
  • Digossina
  • 12β-hydroxydigitoxin
  • Digoxinum
Brand Names
  • Pediatric Digoxin Injection C.S.D.
  • Jamp Digoxin
  • Lanoxin Inj 0.05mg/ml Pediatric
  • Digox
  • Lanoxin Tab 0.0625mg
IndicationDigoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients.[L9143] 2) To increase myocardial contraction in children diagnosed with heart failure.[L9143] 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.[L9143] In adults with heart failure, when it is clinically possible, digoxin should be administered in conjunction with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor for optimum effects.[L9143]
  • Agents causing hyperkalemia
  • Antiarrhythmic agents
  • Bradycardia-Causing Agents
  • BSEP/ABCB11 Substrates
  • BSEP/ABCB11 Substrates with a Narrow Therapeutic Index
CAS number20830-75-5

Drug Targets

NameTarget SequencePharmacological ActionActions
Sodium/potassium-transporting ATPase subunit alpha-1MGKGVGRDKYEPAAVSEQGDKKGKKGKKDRDMDELKKEVSMDDHKLSLDE...unknowninhibitor
Cholesterol side-chain cleavage enzyme, mitochondrialMLAKGLPPRSVLVKGCQTFLSAPREGLGRLRVPTGEGAGISTRSPRPFNE...unknowninhibitor
P-glycoprotein 1MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...unknownsubstrate,inhibitor,inducer
Solute carrier organic anion transporter family member 4C1MKSAKGIENLAFVPSSPDILRRLSASPSQIEVSALSSDPQRENSQPQELQ...unknownsubstrate
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL1751
PubChem 2724385